Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Gyre Therapeutics
Acquired Company
Cullgen
New YorkSan DiegoBiotechnologyHealth CareTherapeuticsBiotechnologyTherapeuticsDescription
Gyre Therapeutics has entered into an agreement to acquire Cullgen in an all-stock transaction valued at approximately $300 million. The merger will make Cullgen a wholly owned subsidiary of Gyre. The transaction is expected to close in early Q2 of 2026, pending regulatory approvals. This merger aims to enhance the capabilities of the combined entity in biopharmaceutical development.
Fundz sees it the moment Gyre Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Cullgen?
Cullgen was acquired by Gyre Therapeutics, based in New York. The deal was reported on October 10, 2026. Gyre Therapeutics is focused on biopharmaceutical innovation. The company specializes in the development of targeted therapies for various diseases. Gyre Therapeutics is privately held and operates in Biotechnology.
When did Gyre Therapeutics acquire Cullgen?
Gyre Therapeutics's acquisition of Cullgen was reported on October 10, 2026. Gyre Therapeutics has entered into an agreement to acquire Cullgen in an all-stock transaction valued at approximately $300 million. The merger will make Cullgen a wholly owned subsidiary of Gyre. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cullgen do?
Cullgen Inc. is a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.